The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab.

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo ...

The addition of obinutuzumab to standard care increased the complete renal response rate by 13.4 percentage points in patients with active proliferative lupus nephritis. Obinutuzumab, an anti-CD20 ...

More patients receiving obinutuzumab plus standard therapy versus standard therapy alone had a complete renal response at week 76. HealthDay News — For patients with active lupus nephritis, ...